(Q34976873)

5 August 2017

1 reference

title

Metastatic pancreatic cancer (English)

1 reference

5 August 2017

1 reference

Matthew H Kulke

1

1 reference

5 August 2017

publication date

1 December 2002

1 reference

Current Treatment Options in Oncology

5 August 2017

published in

1 reference

5 August 2017

volume

3

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

449-457

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-002-0065-5

5 August 2017

exact match

0 references

cites work

Phase II study of gemcitabine in patients with advanced pancreatic cancer

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11864-002-0065-5

Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis

21 January 2018

1 reference

12 December 2020

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma

1 reference

12 December 2020

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

12 December 2020

Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study

1 reference

12 December 2020

Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma

1 reference

12 December 2020

Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan

1 reference

12 December 2020

Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer

1 reference

12 December 2020

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale

1 reference

12 December 2020

Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group.

1 reference

12 December 2020

Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial

1 reference

12 December 2020

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

1 reference

12 December 2020

Palliation of malignant gastric outlet obstruction using an endoscopically placed Wallstent

1 reference

12 December 2020

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1 reference

12 December 2020

Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma

1 reference

12 December 2020

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer

1 reference

12 December 2020

Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer

1 reference

12 December 2020

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

1 reference

12 December 2020

A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma

1 reference

12 December 2020

Cigarette smoking and cancer of the pancreas: evidence from a population-based case-control study in Toronto, Canada

1 reference

12 December 2020

A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin

1 reference

12 December 2020

Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction

1 reference

12 December 2020

Physical activity, obesity, height, and the risk of pancreatic cancer

1 reference

12 December 2020

Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu

1 reference

12 December 2020

Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer

1 reference

12 December 2020

Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer

1 reference

12 December 2020

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study

1 reference

12 December 2020

Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas

1 reference

12 December 2020

A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

[A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer]

1 reference

12 December 2020

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

12 December 2020

10.1007/S11864-002-0065-5

Identifiers

DOI

1 reference

Dimensions Publication ID

5 August 2017

1050555845

0 references

1 reference